Počet záznamů: 1  

Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma

  1. 1.
    SYSNO ASEP0457394
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevCombined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma
    Tvůrce(i) Santarelli, L. (IT)
    Staffolani, S. (IT)
    Strafella, E. (IT)
    Nocchi, L. (IT)
    Manzella, N. (IT)
    Grossi, P. (IT)
    Bracci, M. (IT)
    Pignotti, E. (IT)
    Alleva, R. (IT)
    Borghi, B. (IT)
    Pompili, C. (IT)
    Sabbatini, A. (IT)
    Rubini, C. (IT)
    Zuccatosta, L. (IT)
    Bichisecchi, E. (IT)
    Valentino, M. (IT)
    Horwood, K. (AU)
    Comar, M. (IT)
    Bovenzi, M. (IT)
    Dong, L. F. (AU)
    Neužil, Jiří (BTO-N) RID
    Amati, M. (IT)
    Tomasetti, M. (IT)
    Zdroj.dok.Lung Cancer. - : Elsevier - ISSN 0169-5002
    Roč. 90, č. 3 (2015), s. 457-464
    Poč.str.8 s.
    Jazyk dok.eng - angličtina
    Země vyd.IE - Irsko
    Klíč. slovaMesothelioma ; Lung cancer ; Mesothelin ; BREAST-CANCER METASTASIS
    Vědní obor RIVEB - Genetika a molekulární biologie
    CEPGAP301/10/1937 GA ČR - Grantová agentura ČR
    ED1.1.00/02.0109 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy
    Institucionální podporaBTO-N - RVO:86652036
    UT WOS000366873700013
    DOI10.1016/j.lungcan.2015.09.021
    AnotaceObjectives: Malignant mesothelioma (MM) is a highly aggressive tumor with poor prognosis. A major challenge is the development and application of early and highly reliable diagnostic marker(s). Serum biomarkers, such as 'soluble mesothelin-related proteins' (SMRPs), is the most studied and frequently used in MM. However, the low sensitivity of SMRPs for early MM limits its value; therefore, additional biomarkers are required. In this study, two epigenetically regulated markers in MM (microRNA-126, miR126, and methylated thrombomodulin promoter, Met-TM) were combined with SMRPs and evaluated as a potential strategy to detect MM at an early stage. Materials and methods: A total of 188 subjects, including 45 MM patients, 99 asbestos-exposed subjects, and 44 healthy controls were prospectively enrolled, serum samples collected, and serum levels of SMRPs, miR-126 and Met-TM evaluated. Logistic regression analysis was performed to evaluate the diagnostic value of the three biomarkers. Using this approach, the performance of the '3-biomarker classifier' was tested by calculating the overall probability score of the MM and control samples, respectively, and the ROC curve was generated. Results and conclusion: The combination of the three biomarkers was the best predictor to differentiate MM patients from asbestos-exposed subjects and healthy controls. The accuracy and cancer specificity was confirmed in a second validation cohort and lung cancer population. We propose that the combination of the two epigenetic biomarkers with SMRPs as a diagnosis for early MM overcomes the limitations of using SMRPs alone. (c) 2015 Elsevier Ireland Ltd. All rights reserved.
    PracovištěBiotechnologický ústav
    KontaktMonika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700
    Rok sběru2016
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.